EN
中文 EN
Company News
Home >Newsroom >Company News
ALL
2025
2024
2023
2022
2021
2020
2019
2018
2016
2015
2014
2013
2012
2007
2025.11.13
CanSinoBIO Takes Next Step in Global TB Vaccine Research with Inhaled Vaccine Phase I Trial in Indonesia
2025.11.10
CanSinoBIO Shanghai and PanRu Biotech Sign Licensing Agreement to Expand Applications of Three-Component LNP Delivery System
2025.11.08
Implementing International Cooperation and Regulatory Exchange: Tianjin Medical Products Administration and Indonesia’s BPOM Meet at CanSinoBIO
2025.10.16
Scientific Insight Inspiring Innovation for a Healthier Future——CanSinoBIO Convenes 2025 Annual Scientific Advisory Board Meeting
2025.09.29
CanSinoBIO Expands Innovative Vaccine Impact with Domestic Launch of iPneucia® (PCV13i) and International Shipment of Menhycia®(MCV4)
2025.08.21
Bloomberg | CanSinoBIO’s Xuefeng Yu: Leveraging High-Quality Innovation to Unlock New Growth Opportunities in the Vaccine Industry
2025.07.16
CanSinoBIO's Innovative Recombinant Poliomyelitis Vaccine Obtains Clinical Trial Approval in China
2025.06.20
CanSinoBIO Obtained NDA Approval for its 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine iPneucia®
2025.06.17
CanSinoBIO Launches First-in-Class Three-Component LNP Delivery System: Enhances T Cell Response and Safety, Surpassing Industry Patent Barriers
2025.05.15
CanSinoBIO Obtained Approval for Clinical Trials of Inhaled TB Vaccine in Indonesia
1234569